Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis

Journal of Clinical Pharmacology

Volumn 49, Issue 2, 2009, Pages 162-175

  Zhu, Yaowei ^a   Hu, Chuanpu ^a   Lu, Ming ^a   Liao, Sam ^b   Marini, Joseph C ^a   Yohrling, Jennifer ^a   Yeilding, Newman ^a   Davis, Hugh M ^a   Zhou, Honghui ^a  

^a CENTOCOR INC   (United States)

^b Pharmax Research Inc   (United States)

Author keywords

Interleukin 12 and Interleukin 23 p40; Monoclonal antibody; Population pharmacokinetic modeling; Psoriasis; Ustekinumab

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALEFACEPT; AMLODIPINE; AMOXICILLIN; ATENOLOL; ATORVASTATIN; AZITHROMYCIN; CEFALEXIN; CELECOXIB; CITALOPRAM; COCODAMOL; CYCLOSPORIN; CYTOKINE; DIPHENHYDRAMINE; EFALIZUMAB; ETANERCEPT; HUMAN MONOCLONAL ANTIBODY; HYDROCHLOROTHIAZIDE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROCORTISONE; HYDROXYZINE; IBUPROFEN; INFLIXIMAB; INTERLEUKIN 12P40; INTERLEUKIN 23P40; METHOTREXATE; PLACEBO; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ADULT; AGED; ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BOOTSTRAPPING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMOGRAPHY; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; INDIVIDUALIZATION; INTERINDIVIDUAL VARIABILITY; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BODY WEIGHT; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; MALE; MIDDLE AGED; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 58849118867     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008329556     Document Type: Article

References (38)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996 ; 14: 485-496.
2. Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol. 1994 ; 102: 14S - 18S.
3. Schon MP, Boehncke WH Psoriasis. N Engl J Med. 2005 ; 352: 1899-1912.
4. Lebwohl M. Psoriasis. Lancet. 2003 ; 361: 1197-1204.
5. Chan JR, Blumenschein W., Murphy E., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006 ; 203: 2577-2587.
6. Langrish CL, Chen Y., Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005 ; 201: 233-240.
7. Rogge L., Barberis-Maino L., Biffi M., et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med. 1997 ; 185: 825-831.
8. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003 ; 3: 133-146.
9. Wilson NJ, Boniface K., Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007 ; 8: 950-957.
10. Gottlieb AB, Cooper KD, McCormick TS, et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin. 2007 ; 23: 1081-1092.
11. Kauffman CL, Aria N., Toichi E., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004 ; 123: 1037-1044.
12. Krueger GG, Langley RG, Leonardi C., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007 ; 356: 580-592.
13. Leonardi CL, Kimball AB, Papp KA,, et al. for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 ; 371: 1665-1674.
14. Papp KA, Langley RG, Lebwohl M.,, et al. for the PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008 ; 371: 1675-1684.
15. Zhu YW, Zhang J., Pendley C., et al. Pharmacokinetics of a human monoclonal antibody to IL-12 p40 following single intravenous infusion in patients with moderate to severe plaque-type psoriasis. Clin Pharmacol Ther. 2004 ; 75: P9.
16. Zhu YW, Yeilding N., Guzzo C., Marini J., Mascelli MA, Davis H. Pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation of CNTO 1275 in subjects with moderate to severe psoriasis vulgaris. J Clin Pharmacol. 2007 ; 47: 1203.
17. Geng D., Shankar G., Schantz A., Rajadhyaksha M., Davis H., Wagner C. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal. 2005 ; 39: 364-375.
18. Boeckman A., Sheiner L., Beal S. NONMEM Users Guide. San Francisco: University of California at San Francisco ; 1992-1999.
19. Parke J., Holford NGH, Charles BG A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999 ; 59: 19-29.
20. Nestorov I., Zitnik R., Ludden T. Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. J Pharmacokinet Pharmacodyn. 2004 ; 31: 463-490.
21. Sun YN, Lu JF, Joshi A., Compton P., Kwon P., Bruno RA Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol. 2005 ; 45: 468-476.
22. Baxter LT, Zhu H., Mackensen DG, Jain RK Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994 ; 54: 1517-1528.
23. Lobo ED, Hansen RJ, Balthasar JP Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004 ; 93: 2645-2668.
24. Molthoff CFM, Pinedo HM, Schluper HMM, Nijman HW, Boven E. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab′)2 fragments in experimental ovarian cancer. Br J Cancer. 1992 ; 65: 677-683.
25. Mascelli MA, Zhou H., Sweet R., et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol. 2007 ; 47: 553-565.
26. Frazer JK, Capra JD Immunoglobulins: structure and function. In: Paul WE, ed. Fundamental Immunology. 4 th ed. Philadelphia: Lippincott-Raven ; 1999: 37-74.
27. Brambell FW The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet. 1966 ; 288: 1087-1093.
28. Tabrizi MA, Tseng CML, Roskos LK Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006 ; 11: 81-88.
29. Ng CM, Bruno R., Combs D., Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005 ; 45: 792-801.
30. Alexander E., Pinto J., Pal GS, Kamath N., Kuruvilla M. Disease concomitance in psoriasis: a clinical study of 61 cases. Indian J Dermatol Venereol Leprol. 2001 ; 67: 66-68.
31. Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat. 2005 ; 16: 319-323.
32. Moriguchi P., Sannomiya P., Lara PF, Oliveira-Filho RM, Greco KV, Sudo-Hayashi LS Lymphatic system changes in diabetes mellitus: role of insulin and hyperglycemia. Diabetes Metab Res Rev. 2005 ; 21: 150-157.
33. Valensi P., Cohen-Boulakia F., Attali JR, Behar A. Changes in capillary permeability in diabetic patients. Clin Hemorheol Microcirc. 1997 ; 17: 389-394.
34. Fauchald P., Norseth J., Jervell J. Transcapillary colloid osmotic gradient, plasma volume and interstitial fluid volume in long-term Type 1 (insulin-dependent) diabetes. Diabetologia. 1985 ; 28: 269-273.
35. Kennedy DM, Skillen AW, Self CH Glycation increases the vascular clearance rate of IgG in mice. Clin Exp Immunol. 1993 ; 94: 447-451.
36. Seitz K., Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007 ; 47: 1104-1118.
37. Zhou H. Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures ? J Clin Pharmacol. 2006 ; 46: 1268-1289.
38. Hu C., Zhou H. An improved approach for confirmatory phase III population pharmacokinetic analysis. J Clin Pharmacol. 2008 ; 48: 812-822.